<DOC>
	<DOCNO>NCT00002839</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell allow doctor preserve part body cancer start . It yet know regimen cisplatin fluorouracil combine radiation therapy effective treat resectable cancer hypopharynx larynx . PURPOSE : Randomized phase III trial compare effectiveness two regimen cisplatin fluorouracil combine radiation therapy preserve larynx patient resectable cancer hypopharynx larynx .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy To Preserve Larynx Patients With Cancer Hypopharynx Larynx</brief_title>
	<detailed_description>OBJECTIVES : - Compare relapse-free survival larynx preservation patient resectable hypopharyngeal laryngeal cancer treat sequential v alternate cisplatin fluorouracil radiotherapy . - Compare health-related quality life patient treat regimen . - Compare cost-effectiveness regimen . OUTLINE : This randomize , multicenter study . Patients stratify performance status , disease site , tumor stage , node stage , center . Patients randomize one two treatment arm . Both group may receive either conventional radiotherapy single daily fraction , 5 day per week , 7 week ( option 1 ) hyperfractionated radiotherapy 2 daily fraction , 5 day per week , 4-5 week ( option 2 ) , accord institutional policy . - Arm I : Patients receive cisplatin fluorouracil every 3 week . Patients complete partial response day 42 receive 2 additional course chemotherapy follow 7 week radiotherapy begin day 80 . After radiotherapy , patient complete remission enter follow-up ; partial remission proceed surgery . Patients stable progressive disease proceed immediately surgery without postoperative radiotherapy . - Arm II : Patients receive cisplatin fluorouracil every 3 week 4 course . Patients treat radiotherapy option 1 evaluate 2 month completion radiotherapy ; complete remission enter follow-up others proceed surgery . Patients treat option 2 evaluate day 42 ; partial complete response complete chemoradiotherapy evaluate treat like option 1 patient . Patients stable progressive disease day 42 proceed surgery without third course chemotherapy week 7 . Patients follow every 3 month 3 year least every 6 month thereafter . PROJECTED ACCRUAL : A total 564 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma head neck , include : Stage III/IV cancer glottic supraglottic larynx Eligible T4 tumor define : Bulging vallecula Bulging hyothyroid membrane Minimal thyroid cartilage invasion suspicion invasion image Stage II/III/IV cancer pyriform sinus hypopharyngeal aspect aryepiglottic fold ( without extension postcricoid area ) No massive destruction thyroid cartilage No continuity primary tumor lymph node Operable first attempt ( assess head neck surgeon ) classical total laryngectomy without partial pharyngectomy No requirement extend surgery ( circumferential pharyngolaryngectomy ) No tumor suitable partial ( functional ) surgery require extend surgery necessitates kind flap closure No N2c tumor unless requirement bilateral resection internal jugular vein Measurable evaluable disease panendoscopy CT scan MRI Esophagoscopy require Bronchofiberscopy recommend No requirement tracheotomy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR WHO 02 Hematopoietic : WBC least 4,000/mm^3 Hepatic : Bilirubin great 2.0 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : No medical , psychological , geographical condition precludes study compliance No serious nonmalignant systemic disease No second malignancy except : Carcinoma situ cervix Adequately treat nonmelanomatous skin cancer No poor nutritional status unlikely restore fair status within 3 week No contraindication CT scan general anesthesia PRIOR CONCURRENT THERAPY : Biologic therapy No prior anticancer biologic therapy Chemotherapy No prior anticancer chemotherapy Endocrine therapy No prior anticancer endocrine therapy Radiotherapy No prior anticancer radiotherapy Surgery See Disease Characteristics Other No prior anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
</DOC>